Lannett

OverviewSuggest Edit

Lannett is a company that specializes in pharmaceutical product families. It offers generic pharmaceutical products in different forms such as capsules, tablets, liquids, powders, and sprays. The company serves schools, hospitals, veterans, institutions, rehabilitation centers, cancer research, as well as the local fire and police departments.
TypePublic
Founded1942
HQTrevose, PA, USMap
Websitelannett.com
Employee Ratings2.2More
Overall CultureCMore
View Jobs (27)

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2021)810(-15%)
Job Openings27
Revenue (FY, 2020)$545.7 M(-16%)
Share Price (May 2022)$0.5(+15%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Lannett

Timothy C. Crew

Timothy C. Crew

Chief Executive Officer and Director
John Kozlowski

John Kozlowski

Vice President of Finance and Chief Financial Officer
Samuel H. Israel

Samuel H. Israel

Chief Legal Officer and General Counsel
Maureen Cavanaugh

Maureen Cavanaugh

Senior VP & Chief Commercial Operations Officer
John M. Abt

John M. Abt

VP & Chief Quality Operations Officer
Patrick G. Lepore

Patrick G. Lepore

Chairman
Show more

Lannett Office Locations

Lannett has offices in Trevose and Philadelphia
Trevose, PA, US (HQ)
1150 Northbrook Dr #155, Trevose
Philadelphia, PA, US
9000 State Rd.
Show all (2)

Lannett Financials and Metrics

Lannett Revenue

Lannett's revenue was reported to be $545.74 m in FY, 2020
USD

Revenue (Q2, 2021)

133.9m

Net income (Q2, 2021)

(171.9m)

EBIT (Q2, 2021)

(216.6m)

Market capitalization (13-May-2022)

23.4m

Closing stock price (13-May-2022)

0.5

Cash (31-Dec-2020)

34.2m

EV

616.2m
Lannett's current market capitalization is $23.4 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

123.0m151.1m273.8m406.8m542.5m633.3m684.6m655.4m545.7m

Revenue growth, %

49%33%

Cost of goods sold

82.0m93.6m99.3m100.5m

Gross profit

41.0m57.4m174.5m306.4m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

28.9m27.7m30.7m35.3m36.6m39.0m45.8m67.3m80.0m93.4m114.8m99.4m106.4m127.1m140.1m161.6m170.9m161.7m155.0m184.3m174.4m155.1m193.7m172.8m127.3m136.1m144.4m126.5m133.9m

Cost of goods sold

19.7m19.8m19.3m21.2m22.6m23.3m24.4m26.3m23.9m21.8m27.6m23.7m51.8m

Gross profit

9.1m8.0m11.4m14.1m13.9m15.7m21.4m41.0m56.1m71.6m87.2m75.6m75.3m

Gross profit Margin, %

32%29%37%40%38%40%47%61%70%77%76%76%59%
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

22.6m42.7m105.6m200.3m224.8m117.7m98.6m140.2m144.3m

Accounts Receivable

42.2m26.4m61.3m91.1m211.7m204.1m252.7m164.8m125.7m

Prepaid Expenses

1.0m1.2m1.8m3.2m6.6m4.9m13.6m

Inventories

27.1m32.5m44.8m46.2m114.9m122.6m141.6m144.0m142.9m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

17.5m19.9m19.0m26.4m31.5m33.1m35.7m94.4m84.1m137.4m170.6m208.8m207.8m178.8m225.4m241.7m247.3m132.0m92.5m139.9m114.0m150.3m163.8m205.2m101.0m119.2m101.5m108.8m34.2m

Accounts Receivable

34.6m36.7m37.5m42.1m41.4m39.8m29.7m51.4m59.2m75.8m90.6m79.7m107.2m235.0m183.6m190.5m223.0m215.2m243.3m256.7m238.8m205.4m275.4m151.8m173.1m158.5m180.4m138.8m160.1m

Prepaid Expenses

1.6m1.8m1.5m2.1m1.3m1.9m2.8m2.3m2.2m3.3m4.2m3.2m4.5m24.0m7.7m7.9m7.3m9.3m6.5m10.0m7.9m8.0m7.2m7.0m8.7m

Inventories

26.5m23.9m28.0m27.6m30.7m32.8m34.5m35.8m41.4m44.1m42.6m42.5m45.2m124.0m116.5m127.8m130.2m123.8m125.4m135.6m133.3m145.9m136.1m136.4m149.2m152.1m136.0m156.5m122.2m
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

4.0m13.4m57.2m150.0m44.9m(547.0k)28.7m(272.1m)(33.4m)

Depreciation and Amortization

5.7m6.2m6.0m5.6m33.4m55.3m55.1m55.6m56.3m

Inventories

(161.0k)(5.5m)(12.3m)1.4m15.3m(7.7m)(19.0m)(2.3m)1.1m

Accounts Payable

(389.0k)4.7m(1.7m)(2.5m)(3.7m)5.0m(5.0m)(43.3m)19.0m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

222.1k851.7k2.6m2.9m5.8m9.8m(6.0m)10.6m33.6m35.0m79.8m116.0m33.2m46.7m41.3m(29.4m)(21.2m)(6.3m)13.3m27.3m40.0m(287.5m)(275.2m)(264.5m)(12.2m)(7.1m)(23.7m)(6.5m)(178.4m)

Depreciation and Amortization

1.4m2.8m4.2m1.5m3.1m4.6m1.6m3.2m4.8m1.3m2.6m4.1m1.9m8.1m20.1m14.3m28.0m41.6m13.8m27.4m40.6m14.8m28.6m42.0m12.8m26.9m41.4m14.3m28.7m

Inventories

427.7k3.0m(1.1m)(542.0k)(3.6m)(5.8m)(2.0m)(3.2m)(8.8m)774.0k2.2m2.4m960.0k6.0m13.3m(12.8m)(15.3m)(8.9m)(2.8m)(13.0m)(10.7m)(9.8m)2.2m1.8m(5.2m)(8.1m)8.0m(13.6m)(2.6m)

Accounts Payable

(3.0m)(4.7m)(2.6m)(5.3m)636.0k(2.3m)(6.0m)(3.4m)(1.4m)(7.0m)(1.9m)(4.0m)(1.9m)(4.9m)(5.4m)9.3m9.1m11.6m2.0m28.9m5.8m(7.3m)3.7m(25.0m)13.4m17.4m20.3m15.0m10.1m
show all
USDQ1, 2012

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.4 x
Show all financial metrics

Lannett Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Lannett Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Lannett Online and Social Media Presence

Lannett's Trends

Embed Graph

Lannett Company Culture

  • Overall Culture

    C

    66/100

  • CEO Rating

    B

    70/100

  • Compensation

    B

    74/100

Learn more on Comparably

Lannett News and Updates

February 19, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company, Inc. - LCI

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...
August 16, 2019

Notice For A Proposed Class Action Settlement Involving Individuals Who Purchased Or Acquired Common Stock Of Lannett Company, Inc.

SEATTLE, Aug. 16, 2019 /PRNewswire/ -- UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA Case No. 2:18-cv-03635-MAK ROBERT STROUGO, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. LANNETT COMPANY, INC., TIMOTHY C. CREW, and MARTIN P. GALVAN,...
May 13, 2019

LANNETT INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lannett Company, Inc. To Contact The Firm

NEW YORK, May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lannett Company, Inc. ("Lannett" or the "Company") (NYSE:LCI). If you invested in Lannett stock or options and would like to discuss your legal...
November 12, 2018

Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st

BRIDGEWATER, N.J., Nov. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take over the distribution and marketing of Levothyroxine sodium...
September 13, 2018

LCI LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Lannett Company, Inc. - LCI

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Lannett Company, Inc. (NYSE: LCI) from February 7, 2018 through August 17, 2018, inclusive (the "Class...
September 12, 2018

Lifshitz & Miller LLP Announces Investigation of American Express Company, GDS Holdings Limited, Lannett Company, Inc., Mednax, Inc., Menlo Therapeutics Inc., Papa John's International, Inc., Tetraphase Pharmaceuticals, Inc. and Zion Oil & Gas, Inc.

NEW YORK, Sept. 12, 2018 /PRNewswire/ -- American Express Company (AXP) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the FBI probing pricing practices within AXP's foreign-exchange unit. If you are an AXP investor, and would like...
Show more

 Lannett Frequently Asked Questions

  • When was Lannett founded?

    Lannett was founded in 1942.

  • Who are Lannett key executives?

    Lannett's key executives are Timothy C. Crew, John Kozlowski and Samuel H. Israel.

  • How many employees does Lannett have?

    Lannett has 810 employees.

  • What is Lannett revenue?

    Latest Lannett annual revenue is $545.7 m.

  • What is Lannett revenue per employee?

    Latest Lannett revenue per employee is $673.8 k.

  • Who are Lannett competitors?

    Competitors of Lannett include Sarepta Therapeutics, PTC Therapeutics and Ionis Pharmaceuticals.

  • Where is Lannett headquarters?

    Lannett headquarters is located at 1150 Northbrook Dr #155, Trevose, Trevose.

  • Where are Lannett offices?

    Lannett has offices in Trevose and Philadelphia.

  • How many offices does Lannett have?

    Lannett has 2 offices.